A human receptor occupancy assay to measure anti‐PD ‐1 binding in patients with prior anti‐PD ‐1-Reference-Cited by-同舟云学术

A human receptor occupancy assay to measure anti‐PD ‐1 binding in patients with prior anti‐PD ‐1

Published:2021-03-18 Issue: Volume: Page:
ISSN:1552-4922
Container-title:Cytometry Part A
language:en
Short-container-title:Cytometry

Author:

Junker Fabian¹^ORCID,Gulati Pratiksha¹,Wessels Uwe²,Seeber Stefan²,Stubenrauch Kay‐Gunnar²,Codarri‐Deak Laura³,Markert Christoph⁴,Klein Christian³,Camillo Teixeira Priscila¹,Kao Henry⁵

Affiliation:

1. Roche Pharma Research and Early Development, Pharmaceutical Sciences Roche Innovation Center Basel, F. Hoffmann‐La Roche Ltd Basel Switzerland

2. Roche Pharma Research and Early Development, Pharmaceutical Sciences Roche Innovation Center Munich, F. Hoffmann‐La Roche Ltd Penzberg Germany

3. Roche Pharma Research and Early Development, Discovery Oncology, Roche Innovation Center Zurich Schlieren Switzerland

4. Roche Diagnostics GmbH, F. Hoffmann‐La Roche Ltd Penzberg Germany

5. Roche Pharma Research and Early Development, Early Biomarker Development Oncology, Roche Innovation Center Basel, F. Hoffmann‐La Roche Ltd Basel Switzerland

Funder

F. Hoffmann-La Roche

Publisher

Wiley

Subject

Cell Biology,Histology,Pathology and Forensic Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cyto.a.24334

Reference51 articles.

1. Recommendations for the development and validation of flow cytometry‐based receptor occupancy assays;Green CL;Cytometry B Clin Cytom,2016

2. Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development;Liang M;Cytometry B Clin Cytom,2016

3. 2018 White Paper on Recent Issues in Bioanalysis: focus on flow cytometry, gene therapy, cut points and key clarifications on BAV (part 3—LBA/cell‐based assays: immunogenicity, biomarkers and PK assays);Stevenson L;Bioanalysis,2018